Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
Biography and Research Information
OverviewAI-generated summary
Gunaganti Naresh's research focuses on the discovery and chemical optimization of novel therapeutic agents. His work has involved the development of compounds targeting specific molecular pathways implicated in disease. He has investigated potential treatments for Human African Trypanosomiasis and explored inhibitors for FLT3-ITD, including those resistant to existing therapies. His publications also detail the discovery of orally active selective aurora kinase B inhibitors.
Naresh collaborates with researchers at the University of Arkansas for Medical Sciences, including Xiuqi Wang and Phuc Tran. His scholarship metrics include an h-index of 13, with 30 total publications and 563 citations. He is actively publishing, with his most recent work in 2025.
Metrics
- h-index: 13
- Publications: 29
- Citations: 578
Positions
-
Postdoctoral research associate 2018–presentNortheastern University Chemistry and Chemical biology ORCID
-
Postdoctoral research associate publications 2018–2025University of Arkansas for Medical Sciences ORCID
-
Post Doctoral Research fellow 2016–2018University of Arkansas for Medical Sciences College of Pharmacy Pharmaceutical Sciences ORCID
-
Postdoctoral research fellow 2015–2016University of Arizona college of pharmacy ORCID
Selected Publications
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
-
Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma (2020)
-
Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation (2020)
-
Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression (2020)
-
Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma (2019)
-
Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction (2019)
-
Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts (2018)
-
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application (2018)
-
Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives (2018)
-
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT (2018)
Collaboration Network
Top Collaborators
Hongyu Li
The University of Texas at San Antonio Health Science Center (US)
11 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
Showing 5 of 11 shared publications
Brendan Frett
University of Arkansas for Medical Sciences
9 shared publications
In database
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
Showing 5 of 9 shared publications
Naga Rajiv Lakkaniga
University of Arkansas for Medical Sciences (US)
6 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
Showing 5 of 6 shared publications
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
4 shared publications
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
- Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT
Anupreet Kharbanda
University of Arkansas for Medical Sciences
3 shared publications
In database
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
- Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives
Wei Yan
The University of Texas at San Antonio Health Science Center (US)
3 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Nicholas McConnell
University of Arizona (US)
2 shared publications
- Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT
- Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives
Neil P. Shah
University of California, San Francisco (US)
2 shared publications
- Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Francesca Carlomagno
CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) (IT)
2 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Jorge Contreras
Cornell University (US)
2 shared publications
- Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma
- Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma
David Jayabalan
Cornell University (US)
2 shared publications
- Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma
- Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma
Jorge Monge
Cornell University (US)
2 shared publications
- Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma
- Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma
Rubén Niesvizky
Cornell University (US)
2 shared publications
- Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma
- Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma
Mónica L. Guzmán
Cornell University (US)
2 shared publications
- Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma
- Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma
Binyam Belachew
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
Similar Researchers
Based on overlapping research topics
Tsigereda Weldemichael
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Delivery Systems
Disease Mechanisms Research
C-K Lee
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Molecular Biology Techniques and Applications
Hubay Ca
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Molecular Biology Techniques and Applications
Fengping Lv
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Rachael Oluwakamiye Abolade
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Disease Mechanisms Research
R W Petty
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Delivery Systems
Molecular Biology Techniques and Applications